Near-cure in patients with Gadolinium deposition disease undergoing intravenous DTPA chelation.
Gadolinium
Gadolinium deposition disease
chelation
flare
near-cure
Journal
Frontiers in toxicology
ISSN: 2673-3080
Titre abrégé: Front Toxicol
Pays: Switzerland
ID NLM: 101777990
Informations de publication
Date de publication:
2024
2024
Historique:
received:
15
01
2024
accepted:
12
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
To demonstrate and evaluate factors contributing to near-cures in patients with Gadolinium Deposition Disease (GDD) undergoing intravenous (IV) DTPA chelation. Patients who had undergone or are currently undergoing DTPA chelation for GDD were included in this report based on their medical records that showed their perceived improvement was at least 80% back to normal. A survey was developed that included factors commonly reported by patients treated in one clinic to determine if these 'near-cured' (pre-MRI baseline health) individuals possessed certain factors and lacked others. The anonymized survey was emailed to these individuals by the principal treating physician, the only investigator not blinded to the subjects. This report describes clinical documentation of patient status and their underlying factors in individuals treated by the primary author, and no research was performed. The survey was sent to sixteen individuals; Fourteen patients completed it (10 females; 41.1 ± 11.2 y/o). The most common factor was the administration of ≤5 lifetime doses of a Gadolinium-Based Contrast Agents (GBCA) (12/14). Unconfounded agents triggering GDD were seen in nine subjects. Most subjects (12/14) initiated chelation in the first year after the causative GBCA, and most (11/14) underwent ≤10 chelations with DTPA. Good healthcare status prior to MRI was observed in 5 subjects. The majority (11/14) described their immune status as strong. Severe physical disability prior to chelation was seen in 1. Subjects with GDD can experience near-cure with IV DTPA chelation. Factors surveyed that predict near-cure include the start of chelation in the first year, few GBCA administrations, and good health status before MRI with GBCA injection. Nonetheless, a few patients with predictors of less successful outcomes still experienced near-cure.
Identifiants
pubmed: 39118832
doi: 10.3389/ftox.2024.1371131
pii: 1371131
pmc: PMC11306197
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1371131Informations de copyright
Copyright © 2024 Semelka and Ramalho.
Déclaration de conflit d'intérêts
RS was employed by Consulting PLLC. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest